Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 ASCO Annual Meeting /
New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia

29th May - 2nd Jun 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 30.05.15
Views: 1715
Rating:

Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA

Prof Chanan-Khan presents, at a press conference at ASCO 2015, a phase II study that has identified the first genomic marker mismatch repair (MMR) deficiency to predict response to the anti-PD-1 antibody pembrolizumab.

Read the news article and watch the interview for more.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation